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CLINICAL PRACTICE GUIDE-lines are systematically de-veloped statements to assistpractitioners with decisions
about appropriate health care for spe-
cific patients’ circumstances.1 Guide-
lines are often assumed to be the
epitome of evidence-based medicine.
Yet, guideline recommendations im-
ply not only an evaluation of the evi-
dence but also a value judgment based
on personal or organizational prefer-
ences regarding the various risks and
benefits of a medical intervention for
a population.2
For more than 20 years, the Ameri-
can College of Cardiology (ACC) and
the AmericanHeart Association (AHA)
have released clinical practice guide-
lines to provide recommendations on
care of patientswith cardiovascular dis-
ease. The ACC/AHA guidelines cur-
rently use a grading schema based on
level of evidence and class of recom-
mendation (available at http://www.acc
.org and http://www.aha.org). The level
of evidence classification combines an
objective description of the existence
and the types of studies supporting the
recommendation and expert consen-
sus, according to 1 of the following 3
categories:
• Level of evidence A: recommenda-
tion based on evidence from multiple
randomized trials or meta-analyses
• Level of evidence B: recommen-
dation based on evidence from a single
randomized trial or nonrandomized
studies
• Level of evidence C: recommen-
dation based on expert opinion, case
studies, or standards of care.
The class of recommendation desig-
nation indicates the strength of a rec-
ommendation and requires guideline
writers not only to make a judgmentSee also p 870 and Patient Page.
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Context The joint cardiovascular practice guidelines of the American College of
Cardiology (ACC) and the American Heart Association (AHA) have become impor-
tant documents for guiding cardiology practice and establishing benchmarks for
quality of care.
Objective To describe the evolution of recommendations in ACC/AHA cardiovas-
cular guidelines and the distribution of recommendations across classes of recommen-
dations and levels of evidence.
Data Sources and Study Selection Data from all ACC/AHA practice guidelines
issued from 1984 to September 2008 were abstracted by personnel in the ACC Sci-
ence andQuality Division. Fifty-three guidelines on 22 topics, including a total of 7196
recommendations, were abstracted.
Data Extraction The number of recommendations and the distribution of classes
of recommendation (I, II, and III) and levels of evidence (A, B, and C) were deter-
mined. The subset of guidelines that were current as of September 2008 was evalu-
ated to describe changes in recommendations between the first and current versions
as well as patterns in levels of evidence used in the current versions.
Results Among guidelines with at least 1 revision or update by September 2008,
the number of recommendations increased from 1330 to 1973 (48%) from the first
to the current version, with the largest increase observed in use of class II recommen-
dations. Considering the 16 current guidelines reporting levels of evidence, only 314
recommendations of 2711 total are classified as level of evidence A (median, 11%),
whereas 1246 (median, 48%) are level of evidence C. Level of evidence significantly
varies across categories of guidelines (disease, intervention, or diagnostic) and across
individual guidelines. Recommendations with level of evidence A are mostly concen-
trated in class I, but only 245 of 1305 class I recommendations have level of evidence
A (median, 19%).
Conclusions Recommendations issued in current ACC/AHA clinical practice
guidelines are largely developed from lower levels of evidence or expert opinion.
The proportion of recommendations for which there is no conclusive evidence is
also growing. These findings highlight the need to improve the process of writing
guidelines and to expand the evidence base from which clinical practice guidelines
are derived.
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about the relative strengths and weak-
nesses of the study data but also tomake
a value judgment about the relative im-
portance of the risks and benefits iden-
tified by the evidence and to synthe-
size conflicting findings amongmultiple
studies. Definitions of the classes of rec-
ommendation are as follows:
• Class I: conditions for which there
is evidence and/or general agreement
that a given procedure or treatment is
useful and effective
• Class II: conditions forwhich there
is conflicting evidence and/or a diver-
gence of opinion about the usefulness/
efficacy of a procedure or treatment
• Class IIa: weight of evidence/
opinion is in favor of usefulness/
efficacy
• Class IIb: usefulness/efficacy is less
well established by evidence/opinion
• Class III: conditions for which
there is evidence and/or general agree-
ment that the procedure/treatment is
not useful/effective and in some cases
may be harmful.
Thus, level of evidence C and class
II indicate, respectively, recommenda-
tions lacking supporting evidence and
those subject to uncertainties about the
appropriate medical decision.
The significant increase in the
quantity of scientific literature con-
cerning cardiovascular disease pub-
lished in recent years (along with the
number of technical and medical
advances)—if aimed to address unre-
solved issues confronting guideline
writers—should have resulted in
guideline recommendations with more
certainty and supporting evidence.
However, whether guidelines have
truly evolved in this direction has not
been systematically investigated.
Thus, we performed a systematic re-
view of the ACC/AHA clinical prac-
tice guidelines issued from1984 to Sep-
tember 2008, with intent of examining
all guidelines published since 1984 for
changes associatedwith the use of class
of recommendation grading schema
both for individual guidelines and cat-
egories of guidelines and evaluating the
adequacy of evidence behind current
guideline recommendations. Our ulti-
mate goalwas to elucidate possible gaps
thatmay limit the evidence-based foun-
dations of ACC/AHA guidelines and to
highlight potential opportunities for im-
provement.
METHODS
All ACC/AHA practice guidelines is-
sued from 1984 to September 2008
were abstracted by personnel in the
ACC Science and Quality Division to
obtain the number of recommenda-
tions within each class of recommen-
dation and the distribution of level of
evidence designations across all guide-
lines. The recommendations are clearly
displayed statements highlighted in
each guideline document and sepa-
rated from the remainder of the text.
Each recommendation contains a spe-
cific designation reflecting the class of
recommendation and the level of evi-
dence. Therefore, the abstraction of the
data performed for this analysis only re-
flected the content of the documents
and was not subject to any judgment
by the abstractors.
Current guidelines were defined as
those posted on the ACC Web site on
September 30, 2008 (http://www.acc
.org/qualityandscience/clinical/topic
/topic.htm#guidelines). The review in-
cluded only comprehensive guideline
documents; focused updates were not
included because these represent an up-
date on a limited number of recom-
mendations and are not reflective of an
entire topic. Guidelines were classi-
fied into the following categories: (1)
disease-based guidelines; (2) interven-
tional procedure–based guidelines; and
(3) diagnostic procedure–based guide-
lines.
The aim of the analysis was to re-
port the distribution of recommenda-
tions across classes of recommenda-
tion and levels of evidence. For current
guidelines for which at least 1 previ-
ous version was available, changes
in the use of classes of recommenda-
tion were evaluated by comparing the
first version with the current version.
Because levels of evidence were intro-
duced only in 1998 and not consis-
tently adopted after they were intro-
duced, only 6 of 17 current guidelines
have a previous version reporting level
of evidence and were suitable to as-
sess changes (atrial fibrillation, heart
failure, stable angina, unstable an-
gina, pacemaker, and percutaneous
coronary intervention).We reported the
use of class of recommendations and
level of evidence in current guide-
lines, defined as above.
Because individual guidelines may
vary widely in the numbers of recom-
mendations, in order to weigh equally
each guideline subject within each cat-
egory (ie, disease, interventional, or di-
agnostic), the summary of the distri-
bution of guideline recommendations
within a category across the grading
schemes is shown as the median of the
percentage reported for each guide-
line subject in question. Median val-
ues are also reported to summarize the
changes in each of the categories.
RESULTS
Historical Summary
From 1984 to September 2008, the
ACC/AHA Joint Task Force issued 53
guidelines on 22 topics, including a
total of 7196 recommendations.3-55
Among the 53 guidelines, 24 were dis-
eased-based, 15 were interventional
procedure–based, and 14 were diag-
nostic procedure–based. In 1990, the
class II recommendation was ex-
panded to include classes IIa and IIb.
As of September 2008, 17 of the 53
guidelines were listed as the current
guidelines on the ACC Web site.
Observed Changes Over Time
The ACC/AHA guidelines are periodi-
cally updated. Among the current
guidelines, 12 are revisions of previ-
ously issueddocuments. Themean time
elapsing from the publication of a ver-
sion to the update was 4.6 years (SD,
1.8 years) for disease-based, 5.4 years
(SD, 2.1 years) for interventional pro-
cedure–based, and 8.2 years (SD, 2.4
years) for diagnostic procedure–based
guidelines.
Considering only the current guide-
lines with at least 1 revision, the total
number of recommendations has in-
EVIDENCE UNDERLYING THE ACC/AHA CLINICAL PRACTICE GUIDELINES
832 JAMA, February 25, 2009—Vol 301, No. 8 (Reprinted) ©2009 American Medical Association. All rights reserved.
Downloaded From:  by a University Of North Carolina - Chapel Hill User  on 03/29/2018
creased from 1330 to 1973 (48% in-
crease). The raw increase in number of
recommendations was higher for diag-
nostic procedure–based guidelines (242
additional recommendations) than for
interventional procedure–based (130
additional recommendations) or dis-
ease-based (101 additional recommen-
dations) guidelines (TABLE 1).
Overall, the guidelines shifted to
more class II recommendations and
fewer class III recommendations, while
the use of class I recommendations re-
mained fairly constant over time
(Table 1). Among disease and inter-
ventional guidelines, there was a defi-
nite trend toward more class II recom-
mendations, while the proportion of
class I recommendations decreased. In
diagnostic guidelines, there was a
greater increase in class I recommen-
dations and a decrease in class II rec-
ommendations. In addition, the pro-
portion of class III recommendations
decreased among all guidelines, but es-
pecially for interventional guidelines.
Overall, among current guidelines,
there were 1124 class II recommenda-
tions of 3044 total recommendations,
with a median of 41% (interquartile
range [IQR], 29%-51%) of recommen-
dations in class II across the guide-
lines (TABLE 2).
Level of Evidence
From the introduction of levels of evi-
dence in 1998 through September 2008,
33 guidelines have been released, of
which 27 adopted level of evidence clas-
sification and 6 did not. Among cur-
rent guidelines, only echocardiogra-
phy guidelines17 do not report level of
evidence. The 16 current guidelines re-
porting levels of evidence, comprising
a total of 2711 recommendations, clas-
sify 314 recommendations as level of
evidence A (median, 11% [IQR, 6%-
16%]), whereas 1246 have level of evi-
dence C (median, 48% [IQR, 26%-
57%]) (Table 2).
Among disease-based guidelines,
which generally have a greater propor-
tion of level of evidence A, there is great
variability regarding the use of levels of
evidence. Unstable angina/non–ST-
segment elevation myocardial infarc-
tion,51 heart failure,28 and secondary
prevention guidelines44 havemore than
20% recommendationswith level of evi-
dence A, whereas valvular heart dis-
ease guidelines55 have only 1 recom-
mendation (320 total; 0.3%) with level
of evidence A (Table 2). Individually,
most of the current guidelines include
more than 50% level of evidence C rec-
ommendations, with valvular heart dis-
ease guidelines having the highest per-
centage at 71% (226/320).
Level of evidence A recommenda-
tions are mostly concentrated in class
I (TABLE 3). Nonetheless, among all
1305 class I recommendations of guide-
lines reporting level of evidence, only
245 have level of evidence A (median,
19% [IQR, 11%-30%]); whereas 481
(median, 36% [IQR, 20%-50%]) have
level of evidence C. Only 6 of 17 cur-
rent guidelines have a previous ver-
sion reporting level of evidence. Such
guidelineswere those updatedmore fre-
quently. In this small subset, com-
pared with the first versions reporting
levels of evidence, there was a median
of 6 additional level A recommenda-
tions (IQR, 5-11), 13 level B recom-
mendations (IQR, 3-29), and 24 level
C recommendations (IQR, 14-25).
COMMENT
The ACC/AHA guidelines—as an es-
tablished guidance for management of
cardiovascular disease—have progres-
sively increased the number of recom-
mendations, but these recommenda-
tions largely reflect a lower certainty of
evidence. Furthermore, in current
guidelines, level of evidence C—indi-
cating recommendations based solely
on expert opinion, case studies, or
“standard of care”—is the most fre-
quent designation. These findings point
to consistent gaps in evidence about
medical practices and the need to gen-
erate the research required to close gaps
in knowledge.
Guidelines’ Role and Evolution
of ACC/AHA Practice Guidelines
There is a broad consensus that medi-
cal practice should be based on evi-
dence about outcomes of therapies and
interventions and in agreementwith the
values and preferences of the patient.
This construct of evidence-basedmedi-
cine is predicated on the existence of a
bodyof evidenceofbenefits andrisks that
can be distilled into value judgments
about reasonable actions that are ex-
pressed in clinical practice guidelines.56
During the last decade, the need for
development of guidelines has in-
creased because of advances in devel-
opment of drugs and devices resulting
in greater complexity for the diagno-
sis and treatment of cardiovascular dis-
eases. Potential increases in health costs
and risks due tomarketing-driven, un-
controlled use of novel clinical op-
tions also make guidelines increas-
ingly important.57-60 Furthermore, the
most solid evidence in guidelines is now
used to develop performance mea-
sures, which are used, in turn, to judge
the quality of practice, often in the con-
text of differential payment or public
reporting.
In this setting, the ACC/AHA guide-
lines have assumed a critical role in the
establishmentof standardsof cardiaccare
and in providing benchmarks to define
quality of care.61-63 As such, it is impor-
tant to recognize current limitations of
theACC/AHAguidelines to identify po-
tential areas for improvement.
How Solid Is the Base of Evidence in
CurrentACC/AHAPracticeGuidelines?
The considerable increase in the num-
ber of guideline recommendations
across all guidelines through the cur-
rent versions has not been uniformly
supported by an increased volume of
definitive evidence. In fact, while the
overall proportion of recommenda-
tions labeled as class I has remained
relatively constant, the greatest in-
crease in guidelines recommenda-
tions has been among those subject to
uncertainties, namely class II. Across
guidelines, the median of recommen-
dations in class II is currently 41%.
Level of evidence provides the link
between recommendations and evi-
dence base. Although there is significant
variation among individual guidelines in
EVIDENCE UNDERLYING THE ACC/AHA CLINICAL PRACTICE GUIDELINES
©2009 American Medical Association. All rights reserved. (Reprinted) JAMA, February 25, 2009—Vol 301, No. 8 833
Downloaded From:  by a University Of North Carolina - Chapel Hill User  on 03/29/2018
Table 1. Change in the Number of Recommendations and Distribution Across Classes of Recommendation Between First Guideline Version
and Current Versiona
Guidelines by Year of
Publication
Class I Class II Class III
No./Total (%) Change, % No./Total (%) Change, % No./Total (%) Change, %
Disease guidelines
Atrial fibrillation
20016 46/95 (48.4) 38/95 (40) 11/95 (11.6)
20067 41/111 (36.9) −23.7 55/111 (49.5) 23.9 15/111 (13.5) 16.7
Heart failure
199526 73/127 (57.5) 33/127 (26) 21/127 (16.5)
200528 66/129 (51.2) −11.0 44/129 (34.1) 31.3 19/129 (14.7) −10.9
Perioperative evaluation
199638 8/28 (28.6) 8/28 (28.6) 12/28 (42.9)
200740 13/50 (26.0) −9.3 27/50 (54.0) 88.8 10/50 (20.0) −53.4
Stable angina
199946 67/162 (41.4) 62/162 (38.3) 33/162 (20.4)
200247 78/235 (33.2) −19.7 98/235 (41.7) 9.0 59/235 (25.1) 23.2
Unstable angina
200049 86/139 (61.9) 38/139 (27.3) 15/139 (10.8)
200751 87/128 (62.8) 1.5 29/128 (27.5) 0.7 12/128 (9.7) −10.2
Valvular heart disease
199853 152/321 (47.2) 114/321 (35.4) 55/321 (17.1)
200855 156/320 (48.8) 3.3 124/320 (38.8) 9.5 40/320 (12.5) −26.8
Change in No. of
recommendations
9 84 8
Change in distribution across
classes, median (IQR), %
−10.2
(−17.5 to −1.2)
16.7
(9.1 to 29.5)
−10.6
(−22.8 to 10.0)
Interventional guidelines
CABG
199910 26/56 (46.4) 19/56 (33.9) 11/56 (19.6)
200411 39/56 (46.4) 0 34/56 (40.5) 19.3 11/56 (13.1) −33.3
Pacemaker
198429 27/87 (31.0) 29/87 (33.3) 31/87 (35.6)
200814 38/122 (31.1) 0.4 50/122 (41.0) 23.0 34/122 (27.9) −21.8
PCI
198834 20/69 (29.0) 27/69 (39.1) 22/69 (31.9)
200537 39/136 (28.7) −1.1 69/136 (50.7) 29.7 28/136 (20.6) −35.4
Change in No. of
recommendations
43 78 9
Change in distribution across
classes, median (IQR), %
0
(−0.6 to 0.2)
23.0
(21.2 to 26.4)
−33.3
(−34.4 to −27.6)
Diagnostic guidelines
Echocardiography
199015 58/116 (50.0) 37/116 (31.9) 21/116 (18.1)
200317 190/333 (57.1) 14.1 83/333 (24.9) −21.9 60/333 (8.0) −0.5
Exercise testing
198623 6/32 (18.8) 15/32 (46.9) 11/32 (34.4)
200225 15/71 (21.1) 12.7 37/71 (52.1) 11.2 19/71 (26.8) −22.2
Radionuclide imaging
198641 14/98 (14.3) 78/98 (79.6) 6/98 (6.1)
200343 36/84 (42.9) 200.0 43/84 (51.2) −35.7 5/84 (6.0) −2.8
Change in No. of
recommendations
163 33 46
Change in distribution across
classes, median (IQR), %
14.1
(13.4 to 107.1)
−21.9
(−28.8 to −5.4)
−2.8
(−12.5 to −1.7)
Summary of all guidelines
Change in No. of
recommendations
215 195 63
Change in distribution across
classes, median (IQR), %
0.2
(−9.7 to 5.7)
15.3
(6.9 to 25.4)
−16.4
(−28.4 to −2.2)
Abbreviations: CABG, coronary artery bypass graft; IQR, interquartile range; PCI, percutaneous coronary intervention.
aClass I: conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective. Class II: conditions for which there is conflicting
evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment. Class III: conditions for which there is evidence and/or general agreement that the
procedure or treatment is not useful/effective and in some cases may be harmful.
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available evidence supporting recom-
mendations, the median of level of evi-
dence A recommendations is only 11%
across current guidelines, whereas the
most common grade assigned is level of
evidence C, indicating little to no ob-
jective empirical evidence for the rec-
ommended action. The continued
paucity of adequate evidence from ran-
domized clinical trials ismademost ob-
vious by individual guidelines such as
valvular heart disease,55 which has only
1 level of evidence A recommendation
and yet has 71% level C recommenda-
tions. Thus, expert opinion remains a
dominant driver of clinical practice, par-
ticularly in certain topic areas, high-
lighting the need for clinical research in
these fields. Interestingly, our findings
are reflective of a specialty—cardiol-
ogy—that has a large pool of research
to draw on for its care recommenda-
tions. Guidelines in othermedical areas
in which large clinical trials are per-
formed less frequentlymayhave an even
weaker evidence-based foundation.
Implications for Guideline Writing
The current format of the ACC/AHA
practice guidelines aims to provide rec-
ommendations to a broad set of pos-
sible decision points for each disease or
condition. But whether guidelines
should result fromknowledge only and
should not contain recommendations
such as those in class II or level of evi-
dence C is a matter of debate. Another
organization, the US Preventive Ser-
vices Task Force, has a different policy
in guideline writing that avoids issu-
ing recommendations that are not sup-
ported by evidence.64
Themain argument in favor of com-
prehensive documents is that patient
care needs to be delivered and deci-
sionsmade even in situations that have
not been the subject of large random-
ized clinical trials. Physiciansmay need
more guidance particularly in making
decisions when extensive evidence is
lacking. Alternatively, one might ar-
Table 2. Distribution of Class of Recommendation and Level of Evidence in Current Guidelines
Guidelines Year
No./Total (%)
Class of Recommendationsa Level of Evidenceb
I II III A B C None
Disease guidelines
Atrial fibrillation7 2006 41/111 (36.9) 55/111 (49.5) 15/111 (13.5) 13/111 (11.7) 33/111 (29.7) 65/111 (58.6) 0/111
Heart failure28 2005 66/129 (51.2) 44/129 (4.1) 19/129 (14.7) 34/129 (26.4) 25/129 (19.4) 70/129 (54.3) 0/129
Peripheral artery disease33 2005 147/237 (62.6) 68/237 (28.1) 22/237 (9.4) 36/237 (15.3) 142/237 (60.4) 59/237 (25.1) 0/237
STEMI45 2004 248/422 (58.8) 123/422 (29.1) 51/422 (12.1) 57/422 (13.5) 167/422 (39.6) 199/422 (47.2) 0/422
Perioperative evaluation40 2007 13/50 (26.0) 27/50 (54.0) 10/50 (20.0) 6/50 (12.0) 28/50 (56.0) 16/50 (32.0) 0/50
Secondary prevention44 2006 38/48 (79.2) 10/48 (20.8) 0/48 11/48 (22.9) 33/48 (68.8) 4/48 (8.3) 0/48
Stable angina47 2002 78/235 (33.2) 98/235 (41.7) 59/235 (25.1) 15/235 (6.4) 92/235 (39.1) 128/235 (54.5) 0/235
Supraventricular arrhythmias48 2003 61/147 (41.5) 77/147 (52.4) 9/147 (6.1) 9/147 (6.1) 55/147 (37.4) 83/147 (56.5) 0/147
Unstable angina51 2007 187/298 (62.8) 82/298 (27.5) 29/298 (9.7) 70/298 (23.6) 139/298 (46.8) 88/298 (29.6) 0/298
Valvular heart disease55 2008 156/320 (48.8) 124/320 (38.8) 40/320 (12.5) 1/320 (0.3) 93/320 (29.1) 226/320 (70.6) 0/320
Ventricular arrhythmias and
sudden cardiac death52
2006 103/217 (47.5) 100/217 (46.1) 14/217 (6.5) 21/217 (9.7) 69/217 (31.8) 127/217 (58.5) 0/217
Summary of disease
guidelines, median (IQR), %
48.8
(39.2-60.7)
38.8
(28.6-47.8)
12.1
(8.0-14.1)
12.0
(8.1-19.1)
39.1
(30.8-51.4)
54.3
(30.8-57.5)
0
Interventional guidelines
PCI37 2005 39/136 (28.7) 69/136 (50.7) 28/136 (20.6) 15/136 (11.0) 56/136 (41.2) 65/136 (47.8) 0/136
CABG11 2004 39/84 (46.4) 34/84 (40.5) 11/84 (13.1) 16/84 (19.0) 51/84 (60.7) 17/84 (20.2) 0/84
Pacemaker14 2008 38/122 (31.1) 50/122 (41.0) 34/122 (27.9) 6/122 (4.9) 45/122 (36.9) 71/122 (58.2) 0/122
Summary of interventional
guidelines, median (IQR), %
31.1
(29.9-38.8)
41.0
(40.8-45.9)
20.6
(16.9-24.3)
11.0
(8.0-15.0)
41.2
(39.1-51.0)
47.8
(34.0-53.0)
0
Diagnostic guidelines
Exercise testing25 2002 15/71 (21.1) 37/71 (52.1) 19/71 (26.8) 0/71 3/71 (4.2) 6/71 (8.5) 62/71 (87.3)
Echocardiography17 2003 190/333 (57.1) 83/333 (24.9) 60/333 (18.0) 0/333 0/333 0/333 333/333 (100.0)
Radionuclide imaging43 2003 36/84 (42.9) 43/84 (51.2) 5/84 (6.0) 4/84 (4.8) 58/84 (69.0) 22/115 (26.2) 0/115
Summary of diagnostic
guidelines, median (IQR), %
42.9
(32.0-50.0)
51.2
(38.1-51.7)
18.0
(12.0-22.4)
2.4
(1.2-3.6)
36.6
(20.4-52.8)
17.4
(12.9-21.8)
43.7
(21.8-65.5)
Summary of all guidelines,
median (IQR), %
46.4
(33.2-57.1)
41.0
(29.1-50.7)
13.1
(9.4-20.0)
11.4
(5.8-16.2)
39.4
(31.3-57.1)
47.5
(25.9-56.9)
0
Abbreviations: CABG, coronary artery bypass graft; IQR, interquartile range; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
aClass I: conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective. Class II: conditions for which there is conflicting
evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment. Class III: conditions for which there is evidence and/or general agreement that the
procedure or treatment is not useful/effective and in some cases may be harmful.
bLevel of evidence A: recommendation based on evidence from multiple randomized trials or meta-analyses. Level of evidence B: recommendation based on evidence from a single
randomized trial or nonrandomized studies. Level of evidence C: recommendation based on expert opinion, case studies, or standard of care. Summary statistics include only guide-
lines reporting level of evidence.
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gue that in the absence of evidence, cli-
nicians should make decisions mostly
based on their personal clinical judg-
ment—rather than on the consensus of
a group of clinical experts—as well as
on their direct knowledge of a specific
patient’s clinical situation. The possi-
bility that an increase in recommenda-
tions in class II might lead to greater
use of procedures or interventions in
the setting of an uncertain benefit has
not yet been widely studied. In 1 re-
port from the ACC National Cardio-
vascular Data Registry, nearly 30% of
percutaneous coronary interventions
performed in the United States, ac-
counting for more than 115 000 pro-
cedures, were done under a class II
ACC/AHA indication.65 In another
study, 39.1% of cardiac catheteriza-
tions after an acute myocardial infarc-
tion, accounting for nearly 45 000 pro-
cedures, were classified as class II
indications.66
The increase in number of recom-
mendations included in the ACC/
AHA guidelines is likely due to
greater complexity of patient manage-
ment decisions. The result has been
longer documents. Recommendations
with an absence of supporting evi-
dence often require elaboration in
the text to explain their rationale,
which may be as extensive as the
paragraphs reviewing the results of
various clinical trials. Extensive docu-
ments including a large proportion of
uncertain or non–evidence-based rec-
ommendations may make it increas-
ingly difficult, when referring to a
guideline, to locate the most impor-
tant and/or evidence-based informa-
tion relevant to an individual patient.
Thus, they may reduce the implemen-
tation of evidence-based recommen-
dations because the length of the
documents may interfere with prompt
access to guideline information.67-69
Table 3. Distribution of Levels of Evidence Across Classes of Recommendation
Guidelines Year
Class of Recommendation–Level of Evidence, No. (%)a
I-A I-B I-C II-A II-B II-C III-A III-B III-C
Disease guidelines
Atrial fibrillation7 (n = 111) 2006 8 (7.2) 12 (10.8) 21 (18.9) 3 (2.7) 18 (16.2) 34 (30.6) 2 (1.8) 3 (2.7) 10 (9.0)
Heart failure28 (n = 129) 2005 20 (15.5) 13 (10.1) 33 (25.6) 9 (7.0) 11 (8.5) 24 (18.6) 5 (3.9) 1 (0.8) 13 (10.1)
Perioperative evaluation40
(n = 50)
2007 5 (10.0) 5 (10.0) 3 (6.0) 0 19 (38.0) 8 (16.0) 1 (2.0) 4 (8.0) 5 (10.0)
Peripheral artery disease33
(n = 237)
2005 29 (12.2) 88 (37.1) 30 (12.7) 4 (1.7) 43 (18.1) 19 (8.0) 3 (1.3) 9 (3.8) 10 (4.2)
STEMI45 (n = 422) 2004 45 (10.7) 95 (22.5) 108 (25.6) 5 (1.2) 50 (11.8) 68 (16.1) 7 (1.7) 21 (5.0) 23 (5.5)
Secondary prevention44
(n = 48)
2006 10 (20.8) 26 (54.2) 2 (4.2) 1 (2.1) 7 (14.6) 2 (4.2) 0 0 0
Stable angina47 (n = 235) 2002 12 (5.1) 34 (14.5) 32 (13.6) 1 (0.4) 39 (16.6) 58 (24.7) 2 (0.9) 19 (8.1) 38 (16.2)
Supraventricular arrhythmias48
(n = 147)
2003 5 (3.4) 32 (21.8) 24 (16.3) 4 (2.7) 20 (13.6) 53 (36.0) 0 3 (2.0) 6 (4.1)
Unstable angina51 (n = 298) 2007 57 (19.1) 82 (27.5) 47 (15.8) 5 (1.7) 52 (17.4) 25 (8.4) 8 (2.7) 5 (1.7) 16 (5.4)
Valvular heart disease55
(n = 320)
2008 1 (0.3) 59 (18.4) 96 (30.0) 0 25 (7.8) 99 (30.9) 0 9 (2.8) 31 (9.7)
Ventricular arrhythmias and
sudden cardiac death52
(n = 217)
2006 19 (8.8) 32 (14.7) 52 (24.0) 1 (0.5) 35 (16.1) 64 (29.5) 1 (0.5) 2 (0.9) 11 (5.1)
Summary of disease
guidelines, median (IQR), %
10.0
(6.2-13.9)
18.4
(12.6-25.0)
16.3
(13.1-24.8)
1.7
(0.4-2.4)
16.1
(12.7-17.0)
18.6
(12.2-30.1)
1.3
(0.2-1.9)
2.7
(1.3-4.4)
5.5
(4.6-9.8)
Interventional guidelines
PCI37 (n = 136) 2005 14 (10.3) 18 (13.2) 7 (5.1) 1 (0.7) 34 (25.0) 34 (25.0) 0 4 (2.9) 24 (17.6)
CABG11 (n = 84) 2004 12 (14.3) 25 (29.8) 2 (2.4) 4 (4.8) 19 (22.7) 11 (13.1) 0 7 (8.3) 4 (4.8)
Pacemaker14 (n = 122) 2008 4 (3.3) 15 (12.3) 19 (15.6) 1 (0.8) 18 (14.8) 31 (25.4) 1 (0.8) 12 (9.8) 21 (17.2)
Summary of interventional
guidelines, median (IQR), %
10.3
(6.8-12.3)
13.2
(12.8-21.5)
5.1
(3.8-10.4)
0.8
(0.8-2.8)
22.6
(18.7-23.8)
25.0
(19.0-25.2)
0
(0-0.4)
8.3
(5.6-9.1)
17.2
(11.0-17.4)
Diagnostic guidelines
Exercise testing25 (n = 71) 2002 0 2 (2.8) 1 (1.4) 0 1 (1.4) 2 (2.8) 0 0 3 (4.2)
Radionuclide imaging43 (n = 84) 2003 4 (4.8) 28 (33.3) 4 (4.8) 0 29 (34.5) 14 (16.7) 0 1 (1.2) 4 (4.8)
Summary of diagnostic
guidelines, median (IQR), %
2.4
(1.2-3.6)
18.1
(10.4-25.7)
3.1
(2.2-3.9)
0 18.0
(9.7-26.2)
9.7
(6.3-13.2)
2.4
(1.2-3.6)
18.1
(10.4-25.7)
3.1
(2.2-3.9)
Summary of all guidelines,
median (IQR), %
9.4
(4.4-12.7)
16.6
(11.9-28.1)
14.6
(5.1-20.2)
1.0
(0.3-2.2)
16.2
(13.2-19.3)
17.6
(11.9-26.4)
0.6
(0-1.7)
2.8
(1.1-5.7)
5.4
(4.6-10.0)
Abbreviations: CABG, coronary artery bypass graft; IQR, interquartile range; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
aClass I: conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective. Class II: conditions for which there is conflicting
evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment. Class III: conditions for which there is evidence and/or general agreement that the
procedure or treatment is not useful/effective and in some cases may be harmful. Level of evidence A: recommendation based on evidence from multiple randomized trials or meta-
analyses. Level of evidence B: recommendation based on evidence from a single randomized trial or nonrandomized studies. Level of evidence C: recommendation based on expert
opinion, case studies or standard of care. Summary statistics include only guidelines reporting level of evidence.
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To address this problem, the ACC/
AHA Task Force on Practice Guide-
lines has adopted a standard format
by placing the recommendations in
bolded format at the beginning of the
discussion supporting the recommen-
dations and by adding tables and pub-
lishing an executive summary. Other
guideline writing committees may
partially address these issues while
still using the current format by sepa-
rating the summary of clinical trial
data from the interpretation of the
trial data and the rationale used to
justify the recommendations. The
data of the present study should
serve as a basis to evaluate whether
the current format of the guidelines
should be altered to achieve a better
focus on recommendations supported
by objective evidence.
The analysis presented in this ar-
ticle does not address cardiovascular
guidelines released by other major so-
cieties, such as the European Society of
Cardiology (ESC). However, it is likely
that the ESC guidelines and other car-
diovascular guidelines face similar chal-
lenges, particularly concerning the evi-
dence base at the foundation of the
recommendations.Whenguidelines ad-
dress topics with limited or conflict-
ing information, it would not be unex-
pected to find variation on specific
recommendations between docu-
ments released by different societies. In-
deed, differences between the recom-
mendations of the ACC/AHA and ESC
guidelines have been noted in recent
guidelines.51,70-72
The presence of a large proportion
of recommendations with no support-
ing data from randomized clinical trials
requires careful judgment by guide-
line authors. In such circumstances, the
potential for authors’ conflicts of inter-
est, real or perceived, may be impor-
tant. Recommendations based only on
expert opinion may be prone to con-
flicts of interest because, just as clini-
cal trialists have conflicts of interests,
expert clinicians are also those who are
likely to receive honoraria, speakers bu-
reau, consulting fees, or research sup-
port from industry.73,74
It is difficult to quantify the effect of
conflicts of interest in a guideline writ-
ing process, but this was not the sub-
ject of the present study. Certainly, real
or not, the perception among guide-
line readers that financial ties may in-
troduce significant bias in guideline rec-
ommendations has been noted in 1
report.69 A commonly adoptedmethod
to deal with conflicts of interest is add-
ing disclosures, although it is not clear
what effects such disclosures might
have. Disclosing a conflict may make
the authors wary about recommend-
ing products in which they may have
an interest. However, it may also act in
the opposite direction by increasing the
authors’ confidence in recommending
such products once a conflict has been
disclosed.
Major guideline-releasing organiza-
tions have recognized the importance
of having a rigorous policy regarding
conflicts of interest; such policiesman-
age and balance potential conflicts
rather than eliminating them.TheACC/
AHA’s code regulating potential con-
flicts of interest requires the collec-
tion and publication of relationships
with industry by guideline-writing
groups as well as peer reviewers. Rela-
tionships are orally disclosed at every
meeting, votes are recorded for all rec-
ommendations, andmembers with sig-
nificant conflicts abstain from voting,
although they can participate in the dis-
cussion. In addition, theACC/AHA task
force now requires that 30 to 50% of
writing group members have no con-
flicts of interest, and the guidelinewrit-
ing group must be chaired by some-
onewithno conflicts of interest. Finally,
there is no industry funding for guide-
line development, although the ACC
and AHA do receive industry support
for distribution of guideline deriva-
tive products such as pocket guides.
Implications for Research
The findings of this analysis indicate
that the current system generating re-
search is inadequate to satisfy the in-
formation needs of caregivers and pa-
tients in determining benefits and risks
of drugs, devices, and procedures. The
clinical research system in the United
States has been described as a frag-
mented “nonsystem,” with a lack of
common goals, vision, and collabora-
tion.75 In addition, the current clinical
research agenda in the United States is
strongly influenced by industry’s natu-
ral drive to introduce new products.76
There is limited sponsorship of trials to
address questions of comparative ef-
fectiveness or routine clinical prac-
tice. The problem of how to generate
funding for research addressing prac-
tical clinical questions that do not in-
volve a marketable product is cur-
rently unresolved. Parties with an
interest include patients, health care
practitioners, and payers. Frequently,
patient advocacy groups are effective in
raising funds or influencing congres-
sional funding in this regard. There are
examples of public-private partner-
ships addressing practical questions
about technology, such as the Center
for Medical Technology Policy.77 Pay-
ers also may have an interest in fund-
ing research on practical clinical ques-
tions that have direct relevance to
reimbursement decisions.78 Some prac-
tical clinical questionshave been funded
by government agencies such as the
Veterans’ Administration and the Na-
tional Institutes of Health, but the pro-
portion of these budgets available for
practical clinical trials appears to be lim-
ited.79,80 A special agency to foster stud-
ies of comparative effectiveness is also
under consideration.81 The relative pau-
city of funding for practical clinical
questions and comparative effective-
ness studies deserves a prominent place
in policy discussions.
In addition to the paucity of fund-
ing, themarked inefficiency of the cur-
rent research system—resulting in high
costs and extended duration of many
clinical studies—reduces the number
of questions that can be addressed. The
prohibitive costs and time alsomay dis-
courage researchers from developing
and implementing ideas for investiga-
tor-initiated research. In this setting,
even the availability of increased fund-
ing may not guarantee major achieve-
ments in research, as suggested by the
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fact that despite the doubling of expen-
diture in research and development by
industry, productivity in terms of new
US Food and Drug Administration
(FDA) approvals has progressively de-
creased in the last decade.76 Improv-
ing the research systemwill require ac-
tive collaboration among all of the
interested parties—ie, academic, pro-
fessional, and government organiza-
tions and industry. One such collabo-
ration initiated under the FDA’sCritical
Path Program is the Clinical Trials
Transformation Initiative.82 The mis-
sion of this initiative is to identify prac-
tices that, through broad adoption, will
increase the quality and efficiency of
clinical trials.
Key research stakeholders should
collaborate in generating a prioritized
list of research topics. The ACC/AHA
guideline writing group is now assist-
ing in addressing this need by recom-
mending an agenda of research priori-
ties based on important questions that
arise in thewriting process aboutwhere
evidence is needed.
A separate issue is the heavy focus
of industry on efficacy studies in re-
stricted patient populations necessary
to gain FDA approval. Although ini-
tially important to document a drug’s
efficacy without the confounding of
multiple disease states and interacting
medications, it is also necessary to study
new drugs and devices in the broader
population of patients who will re-
ceive them in actual practice. These lat-
ter studies could be initiated while a
drug application is waiting for review
by regulatory authorities (phase 3b) or
shortly after market approval.83 These
more practical clinical trialswould typi-
cally address the questions that physi-
cians and third-party payerswould have
in seeking the proper application of
these new treatments in practice.84
Study Limitations
Our analysis does not account for po-
tential changes over time in the aims of
guidelines writing committees, which
may have influenced the number of rec-
ommendations and the distribution
across classes. Moreover, in 1990, the
class II level of recommendationwas ex-
panded to classes IIa and IIb. With this
definition change, standards and thresh-
olds to determine class of recommenda-
tion may have not remained constant.
Our analysis was designed to evaluate
comprehensive guideline documents;
therefore, the data included in this ar-
ticle do not reflect recommendations in
focusedguidelineupdates thathavebeen
recently released for somedocumentsbut
not yet incorporated into the compre-
hensive documents (eg, stable angina,
percutaneous coronary intervention, ST-
elevationmyocardial infarction). These
focused updates are driven primarily by
resultsof recent randomizedclinical trials
but address only a limited number of is-
sues. The change in levels of evidence
couldbeevaluatedonly ina limitednum-
ber of guidelines, which are those that
are updated more frequently, and may
not be representative of the entire co-
hort of guidelines.
It was beyond the scope of this
article to analyze and compare car-
diovascular guidelines released by
other societies and noncardiovascu-
lar guidelines. Finally, this article
only addressed ACC/AHA practice
guidelines, and the results cannot be
directly applied to other types of
documents, such as “appropriateness
criteria.”
CONCLUSION
Our finding that a large proportion of
recommendations in ACC/AHA guide-
lines are based on lower levels of evi-
dence or expert opinion highlights de-
ficiencies in the sources of definitive
data available for the generation of car-
diovascular guidelines. To remedy this
problem, themedical research commu-
nity needs to streamline clinical trials,
focus on areas of deficient evidence, and
expand funding for clinical research. In
addition, the process of developing
guidelines needs to be improved with
information about the impact that rec-
ommendations based on lower levels of
evidence has on clinical practice. Fi-
nally, clinicians need to exercise cau-
tion when considering recommenda-
tions not supported by solid evidence.
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